{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:28:50Z","timestamp":1784834930427,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2020-06665"],"award-info":[{"award-number":["RGPIN-2020-06665"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dadr.2025.100338","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:13:23Z","timestamp":1745410403000},"page":"100338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Opioid medication doses among safer supply clients: Current safer supply doses and previous OAT experience"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5743-7153","authenticated-orcid":false,"given":"Gillian","family":"Kolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Fajber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perri","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Cipriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.dadr.2025.100338_bib1","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1503\/cmaj.181506","article-title":"Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs","volume":"191","author":"Artenie","year":"2019","journal-title":"CMAJ"},{"key":"10.1016\/j.dadr.2025.100338_bib2","unstructured":"Atkinson, K. 2023. Parkdale Queen West Community Health Center Safer Opioid Supply: 2023 Evaluation Report. https:\/\/pqwchc.org\/ programs-services\/harm-reduction\/safer-opioidsupply- sos-program"},{"key":"10.1016\/j.dadr.2025.100338_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5694\/j.1326-5377.2000.tb139323.x","article-title":"The rediscovery of methadone for cancer pain management","volume":"173","author":"Ayonrinde","year":"2000","journal-title":"Med. J. Aust."},{"issue":"3","key":"10.1016\/j.dadr.2025.100338_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.15288\/jsad.2022.83.309","article-title":"More than a pipe dream? The need to adapt safer opioid supply programs for people who smoke drugs","volume":"83","author":"Bardwell","year":"2022","journal-title":"J. Stud. Alcohol Drugs"},{"issue":"4","key":"10.1016\/j.dadr.2025.100338_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100338_bib6","unstructured":"Bromley, L., Kahan, M., Regenstreif, L., Srivastava, A., Wyman, J., & Dabam, F. 2021. Methadone treatment for people who use fentanyl: Recommendations. META: PHI. \u3008https:\/\/www.metaphi.ca\/wp-content\/uploads\/Guide_MethadoneForFentanyl.pdf\u3009"},{"issue":"9","key":"10.1016\/j.dadr.2025.100338_bib7","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"key":"10.1016\/j.dadr.2025.100338_bib8","article-title":"Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone","volume":"6","author":"Carl","year":"2023","journal-title":"Drug Alcohol Depend. Rep."},{"issue":"5","key":"10.1016\/j.dadr.2025.100338_bib9","doi-asserted-by":"crossref","DOI":"10.15288\/jsad.2020.81.561","article-title":"Use without consequences? A commentary on Bonn et al. (2020)","volume":"81","author":"Carroll","year":"2020","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.dadr.2025.100338_bib10","unstructured":"College of Physicians and Surgeons of British Columbia. 2022. Guidelines: Methadone for Analgesia. \u3008https:\/\/www.cpsbc.ca\/files\/pdf\/DP-Methadone-for-Analgesia-Guidelines.pdf\u3009"},{"issue":"6","key":"10.1016\/j.dadr.2025.100338_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/ADM.0000000000000156","article-title":"Evaluating the effectiveness of first-time methadone maintenance therapy across northern, rural, and urban regions of Ontario, Canada","volume":"9","author":"Eibl","year":"2015","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.dadr.2025.100338_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/CXA.0000000000000192","article-title":"Opioid agonist treatment retention among people initiating methadone and buprenorphine across diverse demographic and geographic subgroups in ontario: a population-based retrospective cohort study","volume":"14","author":"Elnagdi","year":"2023","journal-title":"Can. J. Addict."},{"issue":"1","key":"10.1016\/j.dadr.2025.100338_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"It\u2019s like \u2018liquid handcuffs\u201d: the effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.dadr.2025.100338_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104023","article-title":"Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies","volume":"115","author":"Giang","year":"2023","journal-title":"Int. J. Drug Policy"},{"issue":"36","key":"10.1016\/j.dadr.2025.100338_bib15","doi-asserted-by":"crossref","first-page":"E1233","DOI":"10.1503\/cmaj.220892","article-title":"Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario","volume":"194","author":"Gomes","year":"2022","journal-title":"CMAJ"},{"issue":"7","key":"10.1016\/j.dadr.2025.100338_bib16","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/add.15862","article-title":"Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study","volume":"117","author":"Gomes","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100338_bib17","unstructured":"Government of Ontario. 2024. Ontario Drug Benefit Formulary Search. Retrieved July 11, 2024, from \u3008https:\/\/www.formulary.health.gov.on.ca\/formulary\/\u3009"},{"issue":"1","key":"10.1016\/j.dadr.2025.100338_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-023-00776-z","article-title":"Safer opioid supply: qualitative program evaluation","volume":"20","author":"Haines","year":"2023","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.dadr.2025.100338_bib19","unstructured":"Haines, M., Tefoglou, A., & O\u2019Byrne, P. 2022. Safer Supply Ottawa Evaluation (p. 55). \u3008https:\/\/safersupplyottawa.com\/wp-content\/uploads\/SS-Ottawa-Evaluation-Report-Fall-2022.pdf\u3009"},{"issue":"3","key":"10.1016\/j.dadr.2025.100338_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2021-001497","article-title":"Ethical considerations in quality improvement: key questions and a practical guide","volume":"10","author":"Hunt","year":"2021","journal-title":"BMJ Open Qual."},{"key":"10.1016\/j.dadr.2025.100338_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108202","article-title":"Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study","volume":"216","author":"Ivsins","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.dadr.2025.100338_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11524-020-00489-9","article-title":"It\u2019s helped me a lot, just like to stay alive\u201d: A qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in Vancouver, Canada","volume":"98","author":"Ivsins","year":"2021","journal-title":"J. Urban Health.: Bull. N. Y. Acad. Med."},{"issue":"1","key":"10.1016\/j.dadr.2025.100338_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12954-023-00779-w","article-title":"As long as that place stays open, I\u2019ll stay alive\u201d: accessing injectable opioid agonist treatment during dual public health crises","volume":"20","author":"Jaffe","year":"2023","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.dadr.2025.100338_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104157","article-title":"Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: a qualitative analysis","volume":"120","author":"Karamouzian","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2025.100338_bib25","unstructured":"Kolla, G., & Fajber, K. 2023. Safer Opioid Supply Program: A Comparison of SOS Client Outcomes From 2022 and 2023. London Intercommunity Health Center. \u3008https:\/\/www.nss-aps.ca\/sites\/default\/files\/resources\/2023-LIHC-SOS-Evaluation.pdf\u3009"},{"key":"10.1016\/j.dadr.2025.100338_bib26","unstructured":"Kolla, G., Long, C., Perri, M., Bowra, A., & Penn, R. 2021. Safer Opioid Supply Program: Preliminary Report (p. 44). London Intercommunity Health Center. \u3008https:\/\/lihc.on.ca\/wp-content\/uploads\/2022\/01\/2021-SOS-Evaluation-Full.pdf\u3009"},{"issue":"5","key":"10.1016\/j.dadr.2025.100338_bib27","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/add.15844","article-title":"Addressing the overdose crisis in North America with bold action","volume":"117","author":"Kolla","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100338_bib28","doi-asserted-by":"crossref","unstructured":"Kolla, G., Pauly, B., Cameron, F., Hobbs, H., McCall, J., Majalahti, J., Tombs, K., LeMaister, J., Selfridge, M., & Urbanoski, K. (2024). \u201cIf it wasn\u2019t for them, I don\u2019t think I would be here\u201d: Experiences of the first year of a safer supply program during the dual public health emergencies of COVID and the drug toxicity crisis.","DOI":"10.1186\/s12954-024-01029-3"},{"key":"10.1016\/j.dadr.2025.100338_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104339","article-title":"Prescribed safer opioid supply: a scoping review of the evidence","volume":"125","author":"Ledlie","year":"2024","journal-title":"Int. J. Drug Policy"},{"issue":"5","key":"10.1016\/j.dadr.2025.100338_bib30","doi-asserted-by":"crossref","first-page":"564","DOI":"10.15288\/jsad.2020.81.564","article-title":"Unsafe supply: why making controlled prescription drugs available for unsupervised use will not target the syndemic of HIV, Hepatitis C, overdose, and COVID-19\u2014 a commentary on bonn et al. (2020)","volume":"81","author":"Lembke","year":"2020","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.dadr.2025.100338_bib31","first-page":"88","author":"McMurchy","year":"2022","journal-title":"Assess. Implement. Safer Supply Pilot Proj."},{"key":"10.1016\/j.dadr.2025.100338_bib32","doi-asserted-by":"crossref","unstructured":"McPherson, M.L.. 2018. Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing (2nd ed.). American Society of Health-System Pharmacists.","DOI":"10.37573\/9781585284306"},{"issue":"11","key":"10.1016\/j.dadr.2025.100338_bib33","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1200\/JCO.2001.19.11.2898","article-title":"Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study","volume":"19","author":"Mercadante","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.dadr.2025.100338_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.111067","article-title":"Association of random and observed urine drug screening with long-term retention in opioid treatment programs","volume":"255","author":"Michener","year":"2024","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.dadr.2025.100338_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.11389","article-title":"Opioid coprescription through risk mitigation guidance and opioid agonist treatment receipt","volume":"7","author":"Min","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2025.100338_bib36","article-title":"A preliminary assessment of short-term social and substance use-related outcomes among clients of integrated safer opioid supply pilot programs in Toronto, Canada","author":"Nafeh","year":"2023","journal-title":"Int. J. Ment. Health Addict."},{"issue":"6","key":"10.1016\/j.dadr.2025.100338_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/aje\/kwp186","article-title":"Proportional hazards frailty models for recurrent methadone maintenance treatment","volume":"170","author":"Nosyk","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.dadr.2025.100338_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.dadr.2025.100338_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109375","article-title":"Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada","volume":"233","author":"Nosyk","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"10.1016\/j.dadr.2025.100338_bib40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa0810635","article-title":"Diacetylmorphine versus methadone for the treatment of opioid addiction","volume":"361","author":"Oviedo-Joekes","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.dadr.2025.100338_bib41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","article-title":"Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial","volume":"73","author":"Oviedo-Joekes","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.dadr.2025.100338_bib42","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/add.16096","article-title":"Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study","volume":"118","author":"Paul","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100338_bib43","first-page":"m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ (Clin. Res. Ed. )"},{"key":"10.1016\/j.dadr.2025.100338_bib44","unstructured":"Perri, M., Fajber, K., Guta, A., Strike, C., Kolla, G., 2023. Outcomes from the Safer Supply Program in Kitchener-Waterloo: Report 1. \u3008https:\/\/www.nss-aps.ca\/sites\/default\/files\/resources\/2023-KWSaferSupplyReport1.pdf\u3009."},{"issue":"8","key":"10.1016\/j.dadr.2025.100338_bib45","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/add.14947","article-title":"The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada","volume":"115","author":"Piske","year":"2020","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.dadr.2025.100338_bib46","doi-asserted-by":"crossref","first-page":"562","DOI":"10.15288\/jsad.2020.81.562","article-title":"Putting the horse before the unicorn: a safe supply strategy should begin with partial agonists\u2014a commentary on Bonn et al. (2020)","volume":"81","author":"del Pozo","year":"2020","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.dadr.2025.100338_bib47","unstructured":"Ranger, C., Hobbs, H., Cameron, F., Stuart, H., McCall, J., Sullivan, G., Urbanoski, K., Slaunwhite, A., & Pauly, B. 2021. Co\/Lab Practice Brief: Implementing the Victoria SAFER Initiative (p. 12). Canadian Institute for Substance Use Research, University of Victoria. \u3008https:\/\/www.uvic.ca\/research\/centres\/cisur\/assets\/docs\/colab\/practice-brief-safer.pdf\u3009"},{"issue":"9","key":"10.1016\/j.dadr.2025.100338_bib48","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.dadr.2025.100338_bib49","article-title":"Safer opioid supply programs: hydromorphone prescribing in Ontario as a harm reduction intervention to combat the drug poisoning crisis","author":"Schmidt","year":"2024","journal-title":"Can. J. Public Health"},{"key":"10.1016\/j.dadr.2025.100338_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/dar.13745","article-title":"I don\u2019t chase drugs as much anymore, and I\u2019m not dead\u2019: client reported outcomes associated with safer opioid supply programs in Ontario, Canada","author":"Schmidt","year":"2023","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.dadr.2025.100338_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103709","article-title":"Factors associated with 60-day adherence to \u201csafer supply\u201d opioids prescribed under British Columbia\u2019s interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency","volume":"105","author":"Selfridge","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2025.100338_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076336","article-title":"Effect of risk mitigation guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study","volume":"384","author":"Slaunwhite","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.dadr.2025.100338_bib53","article-title":"Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: an interrupted time series analysis","author":"Socias","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2025.100338_bib54","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. 2024. Opioid- and stimulant-related harms in Canada. Ottawa: Public Health Agency of Canada. \u3008https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/\u3009"},{"key":"10.1016\/j.dadr.2025.100338_bib55","article-title":"Don\u2019t judge a book by its cover: a qualitative study of methadone patients\u2019 experiences of stigma","volume":"11","author":"Woo","year":"2017","journal-title":"Subst. Abus.: Res. Treat."},{"key":"10.1016\/j.dadr.2025.100338_bib56","unstructured":"Xavier J., McGreevy P., McDougall J., Lamb J., A S., Haywood B., et al. 2023 Substance Use Patterns and Safer Supply Preferences Among People Who Use Drugs in British Columbia. Vancouver, BC: BC Centre for Disease Control."},{"issue":"38","key":"10.1016\/j.dadr.2025.100338_bib57","doi-asserted-by":"crossref","first-page":"E1280","DOI":"10.1503\/cmaj.241173","article-title":"Management of opioid use disorder: 2024 update to the national clinical practice guideline","volume":"196","author":"Yakovenko","year":"2024","journal-title":"CMAJ"},{"key":"10.1016\/j.dadr.2025.100338_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103601","article-title":"Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada","volume":"102","author":"Young","year":"2022","journal-title":"Int. J. Drug Policy"}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:13:10Z","timestamp":1762647190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724625000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":58,"alternative-id":["S2772724625000216"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100338","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid medication doses among safer supply clients: Current safer supply doses and previous OAT experience","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100338"}}